All results

23 results for randomized double blind multiple dose placebo controlled study evaluate safety

• TETON

  Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from…

  Ages

  40 Years - N/A

  Sexes

  All

• GALACTIC-1

  This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…

  Ages

  40 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• Teton RIN-PF-301

  Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from…

  Ages

  40 Years - N/A

  Sexes

  All

• Trial of DCA in PDCD

  The objective of this research study is to conduct a pivotal phase 3 trial of treatment with the investigational drug dichloroacetate (DCA) in young children…

  Ages

  6 Months - 17 Years

  Sexes

  All

• RAISE

  This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status…

  Ages

  12 Years - N/A

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All

• ALXN2050-NEPH-201

  This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…

  Ages

  18 Years - 75 Years

  Sexes

  All

• ReCePI

  The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on…

  Ages

  11 Years - N/A

  Sexes

  All

• RECOVER VITAL

  This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community…

  Ages

  18 Years - N/A

  Sexes

  All